Search research articles
Contact Us
Filters
Showing results (91-100 of 97) with videos related to
Page
of 10
Sort By:
You have reached the last page of results.
This site can display upto 97 results.
Neuroscience
|
September 28, 2014
GABA-mediated changes in inter-hemispheric beta frequency activity in early-stage Parkinson's disease
S D Hall, E J Prokic, C J McAllister, et al.
Clinical Pharmacology and Therapeutics
|
April 20, 2007
Cytochrome P450 3A5 genotype is associated with verapamil response in healthy subjects
Y Jin, Y-H Wang, J Miao, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals
|
February 4, 1999
Molecular and physical mechanisms of first-pass extraction
S D Hall, K E Thummel, P B Watkins, et al.
Nature Genetics
|
March 30, 2001
Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression
P Kuehl, J Zhang, Y Lin, et al.
Pharmacogenetics
|
October 23, 2001
The human pregnane X receptor: genomic structure and identification and functional characterization of natural allelic variants
J Zhang, P Kuehl, E D Green, et al.
Clinical Pharmacology and Therapeutics
|
September 20, 2013
Evaluation of various static in vitro-in vivo extrapolation models for risk assessment of the CYP3A inhibition potential of an investigational drug
Md L T Vieira, B Kirby, I Ragueneau-Majlessi, et al.
Pharmacological Reviews
|
June 1, 2004
PharmGKB update: II. CYP3A5, cytochrome P450, family 3, subfamily A, polypeptide 5
E G Schuetz, M V Relling, S Kishi, et al.
Page
of 10
Search research articles
Search
Showing results (91-100 of 97) with videos related to
Sort By:
Page
of 10
You have reached the last page of results.
This site can display upto 97 results.
Neuroscience
|
September 28, 2014
GABA-mediated changes in inter-hemispheric beta frequency activity in early-stage Parkinson's disease
S D Hall, E J Prokic, C J McAllister, et al.
Clinical Pharmacology and Therapeutics
|
April 20, 2007
Cytochrome P450 3A5 genotype is associated with verapamil response in healthy subjects
Y Jin, Y-H Wang, J Miao, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals
|
February 4, 1999
Molecular and physical mechanisms of first-pass extraction
S D Hall, K E Thummel, P B Watkins, et al.
Nature Genetics
|
March 30, 2001
Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression
P Kuehl, J Zhang, Y Lin, et al.
Pharmacogenetics
|
October 23, 2001
The human pregnane X receptor: genomic structure and identification and functional characterization of natural allelic variants
J Zhang, P Kuehl, E D Green, et al.
Clinical Pharmacology and Therapeutics
|
September 20, 2013
Evaluation of various static in vitro-in vivo extrapolation models for risk assessment of the CYP3A inhibition potential of an investigational drug
Md L T Vieira, B Kirby, I Ragueneau-Majlessi, et al.
Pharmacological Reviews
|
June 1, 2004
PharmGKB update: II. CYP3A5, cytochrome P450, family 3, subfamily A, polypeptide 5
E G Schuetz, M V Relling, S Kishi, et al.
Page
of 10